You have 9 free searches left this month | to do more

carfilzomib

Carfilzomib is a drug used to treat Multiple Myeloma, Recurrent Plasma Cell Myeloma, Lymphoma, and other conditions. Carfilzomib is being actively studied in 83 studies and prior, has been studied in 56.

Top SponsorsTop SitesTop Investigators
AmgenHackensack University Medical CenterJonathan Kaufman
M.D. Anderson Cancer CenterMayo ClinicAjai Chari
National Cancer Institute (NCI)Washington University School of MedicineAjay Nooka
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Completed
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
2021-12-03
Dec 3, 2021
C
Terminated
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
2021-06-28
Jun 28, 2021
P
Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
2021-11-25
Nov 25, 2021
L
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Maywood, Illinois
    Loyola University Medical Center
2021-04-23
Apr 23, 2021
i
Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
2021-04-12
Apr 12, 2021
T
Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
2022-01-31
Jan 31, 2022
O
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022
C
Completed
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Edmonton, Alberta, Canada
  • +8 more
2022-02-01
Feb 1, 2022
M
Completed
  • Contiguous Stage II Adult Lymphoblastic Lymphoma
  • +5 more
  • carfilzomib
  • +10 more
  • Sacramento, California
    University of California Davis
2022-03-08
Mar 8, 2022
U
Completed
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Carfilzomib
  • +2 more
  • Davis, California
  • +2 more
2021-04-21
Apr 21, 2021
U
Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
2021-09-15
Sep 15, 2021
B
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Melbourne, Victoria, Australia
  • +2 more
2022-03-01
Mar 1, 2022
H
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +3 more
  • Hackensack, New Jersey
    Hackensack Meridian Health - John Theurer Cancer Center
2022-04-01
Apr 1, 2022
U
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Birmingham, United Kingdom
  • +12 more
2021-10-01
Oct 1, 2021
S
Completed
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
2021-06-21
Jun 21, 2021
P
Recruiting
  • Relapsed Solid Tumors
  • +3 more
  • Carfilzomib
  • +2 more
  • Phoenix, Arizona
  • +7 more
2021-07-06
Jul 6, 2021
T
Completed
  • Myeloma Multiple
  • +3 more
  • Carfilzomib
  • +3 more
  • Afula, Israel
  • +13 more
2022-01-26
Jan 26, 2022
O
Recruiting
  • Myeloma
  • Carfilzomib
  • +3 more
  • Copenhagen, Denmark
  • +3 more
2021-09-15
Sep 15, 2021
O
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +5 more
  • Encinitas, California
  • +6 more
2020-08-12
Aug 12, 2020
E
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Kiel, Germany
  • +2 more
2021-01-25
Jan 25, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
2021-11-18
Nov 18, 2021
M
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-11-01
Nov 1, 2021
N
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • New Haven, Connecticut
  • +4 more
2022-02-01
Feb 1, 2022